Article
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2017
Xu Xiaowei, De Angelis Carmine, Burke Kathleen A, Nardone Agostina, Hu Huizhong, Qin Lanfang, Veeraraghavan Jamunarani, Sethunath Vidyalakshmi, Heiser Laura M, Wang Nicholas, Ng Charlotte K Y, Chen Edward S, Renwick Alexander, Wang Tao, Nanda Sarmistha, Shea Martin, Mitchell Tamika, Rajendran Mahitha, Waters Ian, Zabransky Daniel J, Scott Kenneth L, Gutierrez Carolina, Nagi Chandandeep, Geyer Felipe C, Chamness Gary C, Park Ben H, Shaw Chad A, Hilsenbeck Susan G, Rimawi Mothaffar F, Gray Joe W, Weigelt Britta, Reis-Filho Jorge S, Osborne C Kent, Schiff Rachel
Abstract excerpt
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to investigate a mechanism by which HER2+ breast cancer can reactivate the HER network under potent HER2-targeted therapies.Experimental Design: Resistant derivatives to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.